申请人:Takeda Chemical Industries, Ltd.
公开号:EP0608565A1
公开(公告)日:1994-08-03
The new pyridopyrimidine derivative of the formula (A), wherein n denotes an integer of 0 to 3, Q stands for -(CH₂) m - ( m denotes an integer of 0 to 2), -O-, -S(O)p-( p denotes an integer of 0 to 2 ) or -N-, and R¹ to R⁶ stand for substituents, or its salt is described. Preparation of them and use to endothelin receptor antagonistic agent are exemplified. An endothelin receptor antagonist consisting of said compound is effective as therapeutic composition of acute renal insufficiency, myocardial infarction, hypertension, cerebral infarction, angina pectoris, arteriosclerosis, hepatopathy, pulmonary hypertension, bronchial asthma, organohypofunction occuring during operation or transplantation of organs.
描述了式(A)的新吡啶嘧啶衍生物,其中n表示0至3的整数,Q表示-(CH₂)m-(m表示0至2的整数)、-O-、-S(O)p-(p表示0至2的整数)或-N-,R¹至R⁶表示取代基,或其盐。举例说明了它们的制备及其在内皮素受体拮抗剂中的应用。由所述化合物组成的内皮素受体拮抗剂作为急性肾功能不全、心肌梗塞、高血压、脑梗塞、心绞痛、动脉硬化、肝病、肺动脉高压、支气管哮喘、器官手术或移植过程中发生的器官功能减退的治疗成分是有效的。